Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 115

1.

Author's Reply to Proost: "Challenges in Individualizing Drug Dosage for Intensive Care Unit Patients".

Jelliffe RW.

Clin Pharmacokinet. 2017 Mar;56(3):313-316. doi: 10.1007/s40262-016-0482-4. No abstract available.

PMID:
28035590
2.

Author's reply to Veloso HH Comment on "The Role of Digitalis Pharmacokinetics in Converting Atrial Fibrillation and Flutter to Sinus Rhythm".

Jelliffe RW.

Clin Pharmacokinet. 2016 May;55(5):637-9. doi: 10.1007/s40262-016-0381-8. No abstract available.

PMID:
27000759
3.

Describing Assay Precision-Reciprocal of Variance Is Correct, Not CV Percent: Its Use Should Significantly Improve Laboratory Performance.

Jelliffe RW, Schumitzky A, Bayard D, Fu X, Neely M.

Ther Drug Monit. 2015 Jun;37(3):389-94. doi: 10.1097/FTD.0000000000000168.

4.

Influence of renal function estimation on pharmacokinetic modeling of vancomycin in elderly patients.

Glatard A, Bourguignon L, Jelliffe RW, Maire P, Neely MN, Goutelle S.

Antimicrob Agents Chemother. 2015;59(6):2986-94. doi: 10.1128/AAC.04132-14. Epub 2015 Mar 9.

5.

The Case for Using Higher Doses of First Line Anti-Tuberculosis Drugs to Optimize Efficacy.

Goutelle S, Bourguignon L, Maire P, Jelliffe RW, Neely MN.

Curr Pharm Des. 2014;20(39):6191-206. Review.

PMID:
25190098
6.

The role of digitalis pharmacokinetics in converting atrial fibrillation and flutter to regular sinus rhythm.

Jelliffe RW.

Clin Pharmacokinet. 2014 May;53(5):397-407. doi: 10.1007/s40262-014-0141-6.

7.

A two-compartment population pharmacokinetic-pharmacodynamic model of digoxin in adults, with implications for dosage.

Jelliffe RW, Milman M, Schumitzky A, Bayard D, Van Guilder M.

Ther Drug Monit. 2014 Jun;36(3):387-93. doi: 10.1097/FTD.0000000000000023.

8.

Are vancomycin trough concentrations adequate for optimal dosing?

Neely MN, Youn G, Jones B, Jelliffe RW, Drusano GL, Rodvold KA, Lodise TP.

Antimicrob Agents Chemother. 2014;58(1):309-16. doi: 10.1128/AAC.01653-13. Epub 2013 Oct 28.

9.

Software for dosage individualization of voriconazole for immunocompromised patients.

Hope WW, Vanguilder M, Donnelly JP, Blijlevens NM, Br├╝ggemann RJ, Jelliffe RW, Neely MN.

Antimicrob Agents Chemother. 2013 Apr;57(4):1888-94. doi: 10.1128/AAC.02025-12. Epub 2013 Feb 4.

10.

Population pharmacokinetic and pharmacodynamic modeling for assessing risk of bisphosphonate-related osteonecrosis of the jaw.

Sedghizadeh PP, Jones AC, LaVallee C, Jelliffe RW, Le AD, Lee P, Kiss A, Neely M.

Oral Surg Oral Med Oral Pathol Oral Radiol. 2013 Feb;115(2):224-32. doi: 10.1016/j.oooo.2012.08.455. Epub 2012 Dec 12.

11.

Quantification by energy dispersive x-ray spectroscopy of alendronate in the diseased jaw bone of patients with bisphosphonate-related jaw osteonecrosis.

Schaudinn C, Gorur A, Webster P, Jones AC, Neely M, Jelliffe RW, Le AD, Sedghizadeh PP.

Oral Surg Oral Med Oral Pathol Oral Radiol. 2012 Oct;114(4):480-6. doi: 10.1016/j.oooo.2012.06.006.

PMID:
22986243
12.
13.

Accurate detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric pharmacometric modeling and simulation package for R.

Neely MN, van Guilder MG, Yamada WM, Schumitzky A, Jelliffe RW.

Ther Drug Monit. 2012 Aug;34(4):467-76. doi: 10.1097/FTD.0b013e31825c4ba6.

14.

Comparison of four renal function estimation equations for pharmacokinetic modeling of gentamicin in geriatric patients.

Charhon N, Neely MN, Bourguignon L, Maire P, Jelliffe RW, Goutelle S.

Antimicrob Agents Chemother. 2012 Apr;56(4):1862-9. doi: 10.1128/AAC.05634-11. Epub 2012 Jan 30.

15.

Mathematical modeling of pulmonary tuberculosis therapy: Insights from a prototype model with rifampin.

Goutelle S, Bourguignon L, Jelliffe RW, Conte JE Jr, Maire P.

J Theor Biol. 2011 Aug 7;282(1):80-92. doi: 10.1016/j.jtbi.2011.05.013. Epub 2011 May 18.

PMID:
21605569
16.

Predictability of individualized dosage regimens of carbamazepine and valproate mono- and combination therapy.

Bondareva IB, Jelliffe RW, Andreeva OV, Bondareva KI.

J Clin Pharm Ther. 2011 Oct;36(5):625-36. doi: 10.1111/j.1365-2710.2010.01215.x. Epub 2010 Nov 10.

17.

Intrapulmonary pharmacokinetics and pharmacodynamics of micafungin in adult lung transplant patients.

Walsh TJ, Goutelle S, Jelliffe RW, Golden JA, Little EA, DeVoe C, Mickiene D, Hayes M, Conte JE Jr.

Antimicrob Agents Chemother. 2010 Aug;54(8):3451-9. doi: 10.1128/AAC.01647-09. Epub 2010 May 3.

18.

Visual estimation of patients' body weight in hospital: the more observers, the better?

Goutelle S, Bourguignon L, Bertrand-Passeron N, Jelliffe RW, Maire P.

Pharm World Sci. 2009 Aug;31(4):422-425. doi: 10.1007/s11096-009-9295-y. Epub 2009 Apr 22.

PMID:
19387861
19.

Population modeling and Monte Carlo simulation study of the pharmacokinetics and antituberculosis pharmacodynamics of rifampin in lungs.

Goutelle S, Bourguignon L, Maire PH, Van Guilder M, Conte JE Jr, Jelliffe RW.

Antimicrob Agents Chemother. 2009 Jul;53(7):2974-81. doi: 10.1128/AAC.01520-08. Epub 2009 Apr 20.

20.

A population pharmacokinetic model of epidural lidocaine in geriatric patients: effects of low-dose dopamine.

Kwa A, Sprung J, Guilder MV, Jelliffe RW.

Ther Drug Monit. 2008 Jun;30(3):379-89. doi: 10.1097/FTD.0b013e3181778fa3.

22.

Noninvasive hemodynamic monitoring for combat casualties.

Shoemaker WC, Wo CC, Lu K, Chien LC, Rhee P, Bayard D, Demetriades D, Jelliffe RW.

Mil Med. 2006 Sep;171(9):813-20.

PMID:
17036597
23.

Population pharmacokinetic modelling of carbamazepine in epileptic elderly patients: implications for dosage.

Bondareva IB, Jelliffe RW, Gusev EI, Guekht AB, Melikyan EG, Belousov YB.

J Clin Pharm Ther. 2006 Jun;31(3):211-21.

PMID:
16789986
24.

Outcome prediction by a mathematical model based on noninvasive hemodynamic monitoring.

Shoemaker WC, Wo CC, Lu K, Chien LC, Bayard DS, Belzberg H, Demetriades D, Jelliffe RW.

J Trauma. 2006 Jan;60(1):82-90.

PMID:
16456440
25.

A stochastic control program to predict outcome and to support therapeutic decisions: a preliminary report.

Shoemaker WC, Bayard DS, Wo CC, Botnen A, Ahmedpour N, Gandhi A, Demetriades D, Jelliffe RW.

J Clin Monit Comput. 2005 Jun;19(3):223-30.

PMID:
16244846
26.

Outcome prediction in chest injury by a mathematical search and display program.

Shoemaker WC, Bayard DS, Wo CC, Chan LS, Chien LC, Lu K, Jelliffe RW.

Chest. 2005 Oct;128(4):2739-48.

PMID:
16236950
27.

Mathematical program for outcome prediction and therapeutic support for trauma beginning within 1 hr of admission: a preliminary report.

Shoemaker WC, Bayard DS, Botnen A, Wo CC, Gandhi A, Chien LC, Lu K, Martin MJ, Chan LS, Demetriades D, Ahmadpour N, Jelliffe RW.

Crit Care Med. 2005 Jul;33(7):1499-506.

PMID:
16003054
28.

Stochastic model for outcome prediction in acute illness.

Shoemaker WC, Bayard DS, Wo CC, Botnen A, Chan LS, Chien LC, Lu K, Demetriades D, Belzberg H, Jelliffe RW.

Comput Biol Med. 2006 Jun;36(6):585-600. Epub 2005 Jun 24.

PMID:
15979603
29.

Pharmacokinetics of ethambutol in children and adults with tuberculosis.

Zhu M, Burman WJ, Starke JR, Stambaugh JJ, Steiner P, Bulpitt AE, Ashkin D, Auclair B, Berning SE, Jelliffe RW, Jaresko GS, Peloquin CA.

Int J Tuberc Lung Dis. 2004 Nov;8(11):1360-7.

PMID:
15581206
30.

Population pharmacokinetic modelling of tramadol with application of the NPEM algorithms.

Gan SH, Ismail R, Wan Adnan WA, Zulmi W, Jelliffe RW.

J Clin Pharm Ther. 2004 Oct;29(5):455-63.

PMID:
15482390
31.

A Bayesian approach to tracking patients having changing pharmacokinetic parameters.

Bayard DS, Jelliffe RW.

J Pharmacokinet Pharmacodyn. 2004 Feb;31(1):75-107.

PMID:
15346853
32.

Nonparametric population modeling of valproate pharmacokinetics in epileptic patients using routine serum monitoring data: implications for dosage.

Bondareva IB, Jelliffe RW, Sokolov AV, Tischenkova IF.

J Clin Pharm Ther. 2004 Apr;29(2):105-20.

PMID:
15068399
33.

Recombinant human erythropoietin for the treatment of renal anaemia in children: no justification for bodyweight-adjusted dosage.

Port RE, Kiepe D, Van Guilder M, Jelliffe RW, Mehls O.

Clin Pharmacokinet. 2004;43(1):57-70.

PMID:
14715051
34.

Clinical and pharmacological risk factors for acute graft-versus-host disease after paediatric bone marrow transplantation from matched-sibling or unrelated donors.

Martin P, Bleyzac N, Souillet G, Galambrun C, Bertrand Y, Maire PH, Jelliffe RW, Aulagner G.

Bone Marrow Transplant. 2003 Nov;32(9):881-7.

PMID:
14561988
35.

Relationship between CsA trough blood concentration and severity of acute graft-versus-host disease after paediatric stem cell transplantation from matched-sibling or unrelated donors.

Martin P, Bleyzac N, Souillet G, Galambrun C, Bertrand Y, Maire PH, Jelliffe RW, Aulagner G.

Bone Marrow Transplant. 2003 Oct;32(8):777-84.

PMID:
14520421
36.

[PK/PD modeling of aminoglycoside nephrotoxicity].

Rougier F, Corvaisier S, Ducher M, Claude D, Jelliffe RW, Maire P.

Pathol Biol (Paris). 2003 Jun;51(4):234-6. French.

PMID:
12853000
37.

Population pharmacokinetic analysis of nonlinear behavior of piperacillin during intermittent or continuous infusion in patients with cystic fibrosis.

Vinks AA, Den Hollander JG, Overbeek SE, Jelliffe RW, Mouton JW.

Antimicrob Agents Chemother. 2003 Feb;47(2):541-7.

38.

Distribution and elimination of tobramycin administered in single or multiple daily doses in adult patients with cystic fibrosis.

Aminimanizani A, Beringer PM, Kang J, Tsang L, Jelliffe RW, Shapiro BJ.

J Antimicrob Chemother. 2002 Oct;50(4):553-9.

PMID:
12356801
39.

Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens.

Bleyzac N, Souillet G, Magron P, Janoly A, Martin P, Bertrand Y, Galambrun C, Dai Q, Maire P, Jelliffe RW, Aulagner G.

Bone Marrow Transplant. 2001 Oct;28(8):743-51.

40.

Population pharmacokinetics of amikacin at birth and interindividual variability in renal maturation.

Bleyzac N, Varnier V, Labaune JM, Corvaisier S, Maire P, Jelliffe RW, Putet G, Aulagner G.

Eur J Clin Pharmacol. 2001 Sep;57(6-7):499-504.

PMID:
11699615
41.

Population pharmacokinetics of intravenous and intramuscular streptomycin in patients with tuberculosis.

Zhu M, Burman WJ, Jaresko GS, Berning SE, Jelliffe RW, Peloquin CA.

Pharmacotherapy. 2001 Sep;21(9):1037-45.

PMID:
11560193
42.

Once-a-day individualized amikacin dosing for suspected infection at birth based on population pharmacokinetic models.

Labaune JM, Bleyzac N, Maire P, Jelliffe RW, Boutroy MJ, Aulagner G, Putet G.

Biol Neonate. 2001 Aug;80(2):142-7.

PMID:
11509814
43.
44.

Failure of traditional trough levels to predict tacrolimus concentrations.

Macchi-Andanson M, Charpiat B, Jelliffe RW, Ducerf C, Fourcade N, Baulieux J.

Ther Drug Monit. 2001 Apr;23(2):129-33.

PMID:
11294512
45.

Mixed pharmacokinetic population study and diffusion model to describe ciprofloxacin lung concentrations.

Breilh D, Saux MC, Maire P, Vergnaud JM, Jelliffe RW.

Comput Biol Med. 2001 May;31(3):147-55.

PMID:
11173053
46.

Goal-oriented, model-based drug regimens.

Jelliffe RW, Maire P.

Comput Biol Med. 2001 May;31(3):145-6. No abstract available.

PMID:
11173052
47.

Pharmacokinetics of tobramycin in adults with cystic fibrosis: implications for once-daily administration.

Beringer PM, Vinks AA, Jelliffe RW, Shapiro BJ.

Antimicrob Agents Chemother. 2000 Apr;44(4):809-13.

48.

Pharmacokinetics of ethambutol under fasting conditions, with food, and with antacids.

Peloquin CA, Bulpitt AE, Jaresko GS, Jelliffe RW, Childs JM, Nix DE.

Antimicrob Agents Chemother. 1999 Mar;43(3):568-72.

49.

Pharmacokinetics of pyrazinamide under fasting conditions, with food, and with antacids.

Peloquin CA, Bulpitt AE, Jaresko GS, Jelliffe RW, James GT, Nix DE.

Pharmacotherapy. 1998 Nov-Dec;18(6):1205-11.

PMID:
9855317
50.

Comparisons between antimicrobial pharmacodynamic indices and bacterial killing as described by using the Zhi model.

Corvaisier S, Maire PH, Bouvier d'Yvoire MY, Barbaut X, Bleyzac N, Jelliffe RW.

Antimicrob Agents Chemother. 1998 Jul;42(7):1731-7.

Supplemental Content

Loading ...
Support Center